English  |  正體中文  |  简体中文  |  Items with full text/Total items : 55241/89544 (62%)
Visitors : 10729385      Online Users : 24
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library & TKU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://tkuir.lib.tku.edu.tw:8080/dspace/handle/987654321/41275


    Title: Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia patients
    Authors: Lane, Hsien-Yuan;張玉坤;Chang, Yue-Cune;Cheng, Yiao-Cheung;Liu, Guang-Chyi;Lin, Xing-Ru;Chang, Wen-Ho
    Contributors: 淡江大學數學學系
    Date: 2003-03
    Issue Date: 2010-01-28 07:09:16 (UTC+8)
    Publisher: Physicians Postgraduate Press
    Abstract: Background: Predictors for risperidone-related weight gain remain unclear. This study aimed to identify clinical factors influencing body weight in risperidone-treated patients.
    Method: One hundred forty-six newly hospitalized DSM-IV schizophrenia patients with acute exacerbation entered this prospective, 6-week, repeated-measures trial. The mean ± SD risperidone dose was 4.3 ± 1.4 mg/day at week 6. Efficacy, body weight, and tolerability were measured biweekly. Efficacy was assessed with the Positive and Negative Syndrome Scale (PANSS) and the Nurses' Observation Scale for Inpatient Evaluation (NOSIE). For determining the impacts of possible prognostic factors on body weight, we utilized generalized estimating equation methods to control for other variables and the within-subject dependence over repeated assessments.
    Results: After the effects of other factors (including baseline body weight) were adjusted, every 1-week increase in treatment duration raised body weight by 0.442 kg (p < .0001). Increasing baseline body weight by 1 kg reduced weight gain by 0.022 kg (p < .0001). Every 1-year increment in age decreased body weight by 0.052 kg (p < .001). Undifferentiated subtype predicted higher weight by around 0.9 kg than other subtypes (p < .05). Each 1-mg/day increment in risperidone dosage heightened body weight by 0.084 kg (p = .015). Responders (those with PANSS total-score reduction >= 20%) also had higher weight by 0.513 kg on average (p = .007). Specifically, every 1-point diminution in score in PANSS total, PANSS positive, PANSS negative, PANSS cognitive, and NOSIE increased body weight, on average, by 0.029 kg, 0.057 kg, 0.079 kg, 0.079 kg, and 0.035 kg, respectively (p <= .009). Other variables did not have significant influences.
    Conclusion: The results suggest that lower initial body weight, younger age, undifferentiated subtype, higher dosage, and treatment response (for positive, negative, and cognitive symptoms and social functioning) are associated with greater weight gain in acutely ill patients treated with risperidone. Further studies with longer observation and in other populations are needed.
    Relation: Journal of Clinical Psychiatry 64(3), pp.316-320
    DOI: 10.4088/JCP.v64n0314
    Appears in Collections:[Graduate Institute & Department of Mathematics] Journal Article

    Files in This Item:

    File SizeFormat
    index.html0KbHTML3View/Open

    All items in 機構典藏 are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library & TKU Library IR teams. Copyright ©   - Feedback